Article
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2022
Shi Yuankai, Zhao Yanqiu, Yang Sheng, Zhou Jianying, Zhang Liangming, Chen Gongyan, Fang Jian, Zhu Bo, Li Xingya, Shu Yongqian, Shi Jianhua, Zheng Rongsheng, Wang Donglin, Yu Huiqing, Huang Jianan, Zhuang Zhixiang, Wu Gang, Zhang Longzhen, Guo Zhongliang, Greco Michael, Li Xiao, Zhang Yu
Abstract excerpt
INTRODUCTION: Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations. This study was designed to evaluate the safety, efficacy, and pharmacokinetics of rezivertinib for patients having advanced NSCLC with EGFR T790M mutation. METHODS: This phase 1 study (NCT03386955) was conducted across 20 sites in the People's Republic of China....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.